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Abstract
The improvement in left ventricular assist device (LVAD) technology and scarcity of donor hearts have increased dramatically
the population of the LVAD-supported patients and the probability of those patients to present to the emergency department
with expected and non-expected device-related and patient–device interaction complications. The ageing of the
LVAD-supported patients, mainly those supported with the ‘destination therapy’ indication, increases the risk for those pa-
tients to suffer from other co-morbidities common in the older population. In this second part of the trilogy on the manage-
ment of LVAD-supported patients for the non-LVAD specialist healthcare provider, definitions and structured approach to the
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Bleeding: gastrointestinal and
non-gastrointestinal
Several quality of life-limiting complications are frequently
seen during left ventricular assist device (LVAD) support,
one of the most prominent being bleeding complications.
Incidence
Significant bleeding complications are quite common in LVAD
carriers, incidence varying depending on the source, but
ranging between 22% and 32% during LVAD support or
0.35–0.65 events per patient-year.1,2 These bleeding episodes
were rarely fatal: major bleeding was the cause of death in
2% of the total number of deaths in LVAD patients.3 Recently,
a special focus has been placed on the interaction of blood
components and the device, that is, haemocompatibility, with
increasing awareness of the importance of these interactions
on adverse events.4
Comparisons of the haemocompatibility parameters of dif-
ferent LVADs have been examined, and while pump thrombo-
sis has been present less often in the newest centrifugal-flow
device, the incidence of bleeding was quite similar between
the investigated devices (HMII™, HM3™, and HW™).5,6 On
the other hand, the recent analysis by Kormos et al. noted
a significantly lesser incidence of gastrointestinal bleeding
(GIB) in patients implanted with a centrifugal-flow pump
compared with those who received an axial flow pump.3,4
Similar findings were observed in the MOMENTUM trial,
where a significantly lower incidence of any bleeding, and
GIB in particular, was seen with the centrifugal pump (HM3
vs. HMII).4
Significance and long-term repercussions of
bleeding
Although bleeding complications are usually not fatal, they
are yet clinically significant. Aside from the obvious impair-
ment of quality of life, bleeding usually leads to adjustments
in anticoagulant and anti-platelet therapy, which could po-
tentially increase the probability of pump thrombosis.
Additionally, some of the bleeding episodes will be signifi-
cant enough to require blood transfusions at an average of
2–4 units of packed red blood cells per admission.7 This is
particularly relevant for the bridge-to-transplant candidates,
in whom leuco-irradiated products should be used to reduce
the risk of allo-sensitization caused by the excessive exposure
to blood products that could result in low availability of ap-
propriate heart donors or higher risk for humoral rejection af-
ter heart transplantation (HTx).8,9
Pathophysiology of bleeding
An obvious contributing factor to the bleeding diathesis is the
mandatory anticoagulant and anti-platelet therapy, required
for the normal function of the devices.
Other possible contributing factors have been investi-
gated. A lot of attention has been devoted to the interplay
of the pump with the blood, unified under the name
haemocompatibility.6
One of the examined pathohistological mechanisms for the
induction of bleeding in ventricular assist device-supported
patients is the acquired von Willebrand syndrome (AvWS).
von Willebrand factor (vWF) is large multimeric glycoprotein,
crucial for the process of haemostasis at the site of vascular
injury, where it promotes platelet aggregation and the forma-
tion of platelet plug, also serving as a carrier protein for FVIII
and protecting it from proteolysis.10,11 Patients with impaired
function of vWF, that is, patients with von Willebrand dis-
ease, are prone to bleeding complications. This has previously
been described also in patients with aortic stenosis (Heyde’s
syndrome) and severe heart failure (HF) patients: vWF may
already be degraded in some patients with severe HF at the
time of LVAD implant, and these patients tend to bleed
more.12 A similar pathological process is seen in LVAD
carriers.13
According to the current literature, most all of the LVAD
patients have loss of vWF activity,14 which seems to resolve
after LVAD explant or HTx.15 Different mechanisms have been
hypothesized to contribute to the AvWS in LVAD patients. It
is thought that increased shear stress in the LVAD circulation
may cause the vWF to disentangle, thus exposing domains
promoting proteolysis and degradation of vWF,11 which then
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leads to reduced platelet aggregation. But despite some ex-
tent of AvWS being present in most LVAD patients,13 not all
experience bleeding events.
von Willebrand factor is also considered an inhibitor of
angiogenesis,16 meaning loss of function of vWF could be im-
plicated in promotion of angiodysplasia and arteriovenous
malformations.17 Bansal et al. conducted a prospective
multicentre clinical trial, which demonstrated lower amount
of vWF monomer degradation in the HM3 group.12 Despite
all that, it is yet unclear if assessment for inherited or ac-
quired coagulation disorders is warranted.
Platelet damage and dysfunction observed in LVAD
patients,18–20 thought to be related to shear forces in the
LVAD, could potentially add to the increased risk of bleeding
in this population.
Arteriovenous malformation is anatomically the most fre-
quently reported cause of GIB. Right HF is another potential
risk factor for GIB through the enhanced arteriovenous mal-
formation formation due to elevated portal vein pressure
and coagulopathy associated with congestive hepatic failure.
Non-pulsatile flow was considered a potential predisposing
factor for the development of GIB through the formation of
small intestinal angiodysplasia21; however, studies with par-
tial ventricular support with fully preserved arterial pulse still
reported a high incidence of GIB.22
Improved haemodynamics might have a favourable effect
on suppression of GIB, achieved through the use of optimal
medical therapy or optimizing LVAD speed through ramp
testing23 and medications to control the blood pressure such
us angiotensin-converting enzyme inhibitor and angiotensin
receptor blocker24 and digoxin that was found to be associ-
ated with a decreased incidence of angiodysplasia-related
GIB in patients with continuous-flow (CF)-LVADs.25
The favourable effects of omega-3 unsaturated fatty acids
on angiogenesis and inflammation have been previously
described,26 and in a small study, authors demonstrated that
LVAD patients regularly receiving omega-3 acids had a
greater freedom from GIB compared with controls.27
Risk factors for bleeding in the left ventricular
assist device patient
Some patient populations are at increased risk of bleeding. In
the case of GIB, risk factors include older age,28 lower body
mass index, history of GIB prior to LVAD implant, smoking, el-
evated international normalized ratio (INR), and a low plate-
let count.29 Patients with pre-implant right ventricular
failure have been prone to development of bleeding compli-
cations, possibly due to hepatic congestion and subsequent
coagulopathy. Female sex has also been associated with an
elevated incidence of all bleeding complications after LVAD
implant.28
Diagnosis and treatment options
The extent and the selection of diagnostic and therapeutic
modalities will vary according to the bleeding location, as
well as its severity and the clinical presentation of the
patient.
General conditions
• Depending on the bleeding severity, a temporary interrup-
tion of anticoagulation might be necessary, and, if deemed
clinically justified, reversal of anticoagulation might be
considered.30 These decisions are to be made in close col-
laboration with experienced HF cardiologists, due to the
possible adverse outcomes (i.e. device thrombosis).
• Depending on the bleeding site, different specialists need
to be consulted.
• Previously suggested reduction of pump speed in order to
reduce the sheer stress on blood components30 has been
proven to be ineffective,31 as well as in real life where
we have seen similar bleeding incidence in the newest
generation of devices despite their functioning at lower
speeds.11
Gastrointestinal bleeding
Gastrointestinal bleeding is most frequently seen in LVAD
patients,10 with the incidence ranging between 25% and
35% of patients with events on LVAD support or 0.31–0.56
events per patient-year,4,5,32 and is one of the major causes
of readmission of LVAD patients.10 GIB can occur in any part
of the gastrointestinal (GI) tract, but most often in the upper
portion, proximal to the Treitz ligament.30
Invasive procedures
Diagnostic and treatment options include upper and lower
tract endoscopies, video capsule endoscopy, or deep
enteroscopy.21,30 If these are not able to locate the bleeding
site, angiography is advised (if the patient is unstable, consult
with interventional radiology), or scintigraphy with tagged
red blood cells.
Despite best efforts, sometimes the locus of the GIB re-
mains obscure, even after best endoscopic efforts. Patel
et al. found that hypervascularity of the nasal mucosa was as-
sociated with GI bleeding in LVAD-supported patients sug-
gesting nasal endoscopy as a potential surrogate for
diagnosing AV malformations in the GI tract as in other muco-
sal sites in LVAD carriers.33
Medical treatment
• This includes octreotide, a synthetic somatostatin ana-
logue, which acts through decreased splanchnic blood
flow, increased vascular resistance, improved platelet ag-
gregation, and inhibition of angiogenesis.34 Studies with
octreotide in LVAD carriers showed varying results.29,35
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A protocol of intramuscular application of octreotide in
monthly visits has been evaluated, and authors demon-
strated significant reduction in the frequency of GIB with-
out associated complications and without the need to alter
anticoagulant and anti-platelet therapy.36
Preventive therapies
• Initiation of intravenous proton pump inhibitor is
indicated,10 especially when involvement of the gastric
mucosa is suspected.
• Consider cessation of aspirin and adjustment or cessation
of warfarin depending on the severity of the bleeding ep-
isode and ongoing risk for re-bleeding. This should be per-
formed in close consultation with the LVAD unit. The
presumed assumption that combined use of aspirin and
anticoagulants will lower the risk of thrombus formation
in LVAD-supported patients has been recently questioned
with the low incidence of thrombus formation in the
HM3-supported patients. The ARIES study37 will examine
whether anti-platelet therapy can be safely avoided in
HM3-supported patients, thus reducing the risk of
bleeding.
• The beneficial effect of thalidomide in GIB is associated to
its antiangiogenic properties through the suppression of
vascular endothelial growth factor.38 This therapy for GIB
in LVAD-supported patients is not supported by trials.
Therefore, the potential beneficial effects must outweigh
the potential adverse events associated with thalidomide
therapy (pancytopenia, neuropathy, and thrombo-embolic
events).
• Danazole, a derivative of testosterone, reduces the risk of
bleeding through enhanced concentration of red blood
cells, but has adverse androgenic effects and when
administered with statins may increase the risk of
rhabdomyolysis.39
• Factor VIII concentrates containing FVIII and vWF have
been utilized in some studies, but they have been associ-
ated with device thrombosis.40
• Because several studies have shown resolution of bleeding
complications after HTx, this could also be seen as a




Several large-scale studies found intracranial haemorrhage
(ICH) in 3–11% of LVAD patients represented also as 0.05–
0.07 events per patient-year.41,42 The important issue of ICH
is discussed in detail in the section on ‘Neurological events’
in the subsection on ‘Haemorrhagic stroke’.
Gynaecological bleeding
Given the relatively small proportion of female LVAD pa-
tients: around 20%,3,43 the data on management of
gynaecological bleeding are understandably scarce.
Women seem to have a greater incidence of non-
gynaecological types of bleeding complications (including
gastrointestinal, naso-oropharyngeal, and ICH) compared with
men, but this did not translate into worse survival.2,28,44 In
an analysis by Yavar et al., 10% of patients experienced
gynaecological bleeding requiring transfusions or surgical
interventions.28 Depending on the severity, such episodes
might require interruption of anticoagulant and anti-platelet
treatment, hormonal therapy, or, in extreme cases, surgical
treatment.
The aetiology of increased bleeding diathesis in women is
not yet elucidated.
Other sources of bleeding
Other forms of bleeding that might be encountered in LVAD
carriers include mostly bleeding from the nasal or oral mu-
cosa, seen usually as epistaxis, after teeth extraction, skin
bruises, or haematuria.28 Although these bleeding episodes
are usually treated by other specialists (otolaryngology, oral
surgeons, urologists, etc.), it is advised to include a cardiolo-
gist specialized in managing LVAD patients in the team re-
sponsible for deciding on interruption of anticoagulant or
anti-platelet therapy.
Prevention
Several preventive measures can be undertaken in order to
reduce the number and intensity of bleeding episodes.
Optimal management of anticoagulation is of utmost im-
portance: keeping the INR values within the therapeutic
range could help decrease the risk of bleeding complications.
For this end, patient education and nutritional counselling
are very helpful if the oscillations of INR levels are suspected
to be associated with food interactions (e.g. green and leafy
vegetables). Detailed guidelines on the management of oral
anticoagulation in this population are available.45,46
Coumarin oral anticoagulants such as warfarin are metab-
olized via the CYP2C9,47 which is also a common pathway for
several other drugs commonly used in this patient population
(antidiabetic medication, angiotensin receptor blockers, anti-
convulsive medication, etc.).
Given the common occurrence of polypharmacy in these
patients, caution must be exercised regarding the drug–drug
interactions. In patients with special difficulties maintaining
the INR range, genetic counselling with the identification of
the patient’s metabolic profile is possible.47 Devices for home
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monitoring of INR are available and could potentially be ben-
eficial in achieving optimal INR control.
The excellent results of the MOMENTUM trials,4 demon-
strating significantly reduced burden of device thrombosis
in HM3 carriers, raised the potential need for decreased level
of anticoagulation. This was examined in the MAGENTUM 1
trial, which evaluated lower target INR levels (target INR
1.5–1.9) in 15 HM3 carriers after the sixth post-operative
week. Primary endpoint (event-free survival) was achieved
in 93 ± 6%, but due to the small sample size. This study needs
further validation.48
Adequate blood pressure control is important, for the max-
imization of HF treatment, as well as for the prevention of
bleeding complications—elevated blood pressure (BP) values
were associated with a greater incidence of stroke (both isch-
aemic and haemorrhagic).49,50 Because both hypertensive
and hypotensive BP values have been associated with worse
survival, Cowger et al. suggested in an INTERMACS analysis
that the optimal mean arterial pressure values might be in
the range 70–90 mmHg.51
• GIB is the most frequent source of bleeding in
LVAD-supported patients.
• Considering reversal of the anticoagulation should be
weighed against the risk of pump thrombosis.
• When the blood loss results in low haemoglobin level, try
to avoid blood transfusion in the bridge to transplanta-
tion group, but if needed, use leuco-irradiated blood
products. Try giving iron transfusion and consult the
LVAD centre.
• To lower the incidence of ICH, keep the mean arterial pres-
sure (MAP) below 80 and watch the anticoagulation level
closely keeping it within the advised limits and not earlier.
Neurological events
Stroke is a leading cause of significant morbidity in patients
with LVAD and can be an important contraindication for car-
diac transplantation.52,53 At this point, little is known about
stroke in LVAD patients beyond descriptive epidemiology, in-
cluding associated neurological complications and available
treatment strategies. Patients with LVAD are likely to be at
high risk for recurrent stroke and may have a poor recovery
prognosis than undifferentiated stroke patients due to base-
line severity of illness.
Despite generational advances in engineering of such de-
vices, from large pulsatile mechanisms to smaller CF devices,
the complications related to neurological adverse effects
have not improved substantially. Haemorrhagic and ischae-
mic strokes continue to occur, with a frequency greater than
that observed in patients with advanced HF. This complica-
tion has limited the expansion of such devices to patients
with less severe stages of illness, and the quest to understand
these devastating events and to prevent them is ongoing.
The older devices were larger and had a higher incidence
of thrombosis, and therefore, anticoagulation targets were
different compared with today’s devices. Yet the general inci-
dence of neurological complications, principally stroke, has
not decreased in the contemporary era. This suggests that
the underlying reasons for stroke may be changing as a func-
tion of device era, with causative factors that may have more
to do with vascular biology than simply anticoagulation strat-
egies. The rate of adverse events associated with CF-LVAD
use—specifically, strokes—is as high as 10% of individuals
who are affected by stroke in the first year of support
alone.52 Furthermore, according to the INTERMACS registry,
stroke remains the primary cause of death in the 6–24 months
of the LVAD implantation.53 The stroke rate associated with
pulsatile LVADs was 4 times higher than the rate of patients
managed medically over 2 years.54
In the original trials evaluating the first CF-LVAD (HMII),
the rate of disabling stroke was similar among individuals
managed with the HII CF-LVAD vs. pulsatile devices (17% vs.
14%, respectively, P = 0.56) over 2 years.41 The HW LVAD, a
newer CF-LVAD currently in use, was associated with a higher
stroke rate compared with the HII (29.7% vs. 12.1%,
P < 0.001) over 2 years.5 Finally, in the MOMENTUM trial,
the newest CF-LVAD, the HM3, was found to have a much
lower stroke rate than the HII device (10.1% vs. 19.2%,
P = 0.02) over a 2 year period.55 Thus, refinement of device
technology has led to a reduction in the incidence of stroke
among these patients compared with older pumps.
The causes of strokes with the newer LVADs are unclear
and could relate to (i) clots that pass through the device (as
with atrial fibrillation in patients with a device or with clots
that form within the device or in the proximate ventricle),
(ii) vascular changes as a result of non-pulsatile flow (we
know that reduced pulse pressure with the newer devices in-
creases vascular fragility, so even lower levels of BP can cause
vascular loss of integrity) especially with relation to cerebral
amyloid angiopathy,56 and (iii) rheological causes (new de-
vices create an acquired von Willebrand syndrome and can
predispose to bleeding).14,57
Three types of neurological events are clinically relevant in
LVAD patients: ischaemic strokes, haemorrhagic conversion,
and intra-cerebral haemorrhage.
Ischaemic stroke
Ischaemic strokes can occur because of thrombi that pass
from the heart through the device and into the brain or could
develop in unique locations, such as the aortic surface of the
valves within the sinus of Valsalva, the carotid bulb, and in
some cases septic emboli as a result of infections.58,59
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The most consistent risk factor for ischaemic stroke in
CF-LVADs is systemic infection, which has increased the
risk of stroke by nearly two-fold (39.5% vs. 19.3%,
P = 0.003).60–62 In the INTERMACS registry, independent pre-
operative predictors of ischaemic stroke were female sex and
previous cardiac operation.52 However, when considering
post-operative risk factors, infection and GIB significantly in-
creased the risk of stroke.52
One of the most feared complications of any ischaemic
stroke is bleeding into the area of the infarcted brain
(haemorrhagic conversion/transformation). Consequently,
the risk assessment for resuming anti-thrombotic agents is
often guided by known risk factors in the undifferentiated
ischaemic stroke patient, including infarct size, cardioembolic
aetiology, vessel recanalization, and heparin treatment.63–65
Haemorrhagic stroke
Intracranial haemorrhage is a complication, which usually re-
sults in significant long-term consequences for the patient.
An INTERMACS analysis looking into the incidence of stroke
in LVAD carriers showed that 10% had at least one stroke,
of which nearly 50% were haemorrhagic, leading to a signifi-
cantly worse survival compared with those who suffered an
ischaemic stroke.52 In this analysis, 45% of patients survived
1 month after the ICH, while only 30% survived 1 year. In a
multivariable analysis, heparin-induced thrombocytopenia,
use of intra-aortic balloon pump, female sex, and primary car-
diac diagnosis were significant predictors of ICH. Female sex
has been a predisposing factor in other analysis.8,28,66
Whereas GIB might facilitate a sooner transplantation in
LVAD carriers, ICH more often renders the patient ineligible
for transplant, depending on the residual morbidity.52
There are several possible causes of haemorrhagic stroke
in patients with LVAD, such as anticoagulation, haemorrhagic
conversion after infarction, the acquired von Willebrand syn-
drome as a result of mechanical destruction, and proteolysis
of high-molecular-weight multimers of von Willebrand factor
8 and rupture of histologically fragile vessels caused by the
non-physiological continuous pulseless flow.8,67 It is often un-
clear why a specific CF-LVAD patient develops a specific ICH,
as coagulopathy alone appears neither necessary nor specific.
Intra-cerebral haemorrhages occur in the absence of endo-
carditis with subtherapeutic INRs, whereas supratherapeutic
INR levels do not necessarily lead to haemorrhagic stroke.67
The aetiology of ICH is not completely elucidated. The pre-
sented rates of haemorrhagic strokes are significantly higher
compared with other populations treated with warfarin,
and other studies demonstrated that spontaneous ICH has
been noted in all INR ranges.68–70 Interestingly, all the pa-
tients who developed ICH had concomitant AvWS.71
The incidence of haemorrhagic stroke has also been shown
to reduce with the newest generation of centrifugal-flow
devices.4 This leads to the conclusion that there could be sev-
eral predisposing factors for ICH.
While it is long known from normal pulsatile physiology,
elevated BP during LVAD support has recently been associ-
ated with a higher incidence of intracranial bleeding, and
subsequent mortality, which could indicate BP control as a
beneficial measure in preventing ICH.72,73 Given the
established difficulties in obtaining BP measurements in
LVAD carriers, an alternative to the traditional electronic BP
measuring devices has been investigated, and Doppler-
derived BP measurements have shown to correlate well to in-
vasive systolic BP measuring.74 According to the International
Society for Heart and Lung Transplantation guidelines for
mechanical circulatory support, level of evidence C (expert
opinion), the Doppler-derived BP is to be maintained at
≤80 mmHg.75
The correlation between hypertension and neurological
events was not so obvious in the INTERMACS analysis. Such
a correlation might be device specific as presented in the EN-
DURANCE supplemental study showing that BP management
is associated with reduced stroke rates in HW subjects.61
Maintaining BP in the reference range was associated with
better overall outcomes.51 The authors stress the importance
of avoiding too aggressive BP management with hypotension
as well as hypertension.
Strict management of BP maintaining MAP at 70–90
mmHg49 and anticoagulation targeting INR levels of 2–2.549
are expected to be beneficial preventive strategies for
several complications of LVAD treatment, but this does not
necessarily guarantee absence of bleeding complications49
(see Part 3 for more on anticoagulation in LVAD-supported
patients).
A study by Trachtenberg et al. indicated blood stream in-
fections as a predisposing factor for neurological events, both
ischaemic and haemorrhagic.76
Survival after the haemorrhagic stroke is significantly
reduced and was 45.3%, 34.8%, and 30.3% at 1 month,
6 months, and 1 year, respectively.52
Cerebral microbleeds shown by brain magnetic resonance
imaging are predictive of symptomatic cerebral haemorrhage
in patients with various causes.77
In general population studies, it has been reported that
several factors (e.g. male sex, older age, and elevated BP)
show positive correlations with the number of cerebral
microbleeds,67,78 while correlations with aspirin and warfarin
administration, which are mandatory for patients with LVAD,
remain controversial.79
One small-scale study assessed a treatment protocol for
ICH in LVAD patients, which included observation alone, ob-
servation with suspension of anticoagulation, observation
with reversal of anticoagulation, or reversal of anticoa-
gulation plus surgical intervention.
Reversal of warfarin was performed with fresh frozen
plasma (FFP), prothrombin complex concentrate, vitamin K,
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or a combination. Prothrombin complex concentrate is pre-
ferred in neurosurgical emergencies, given its faster effect.71
Depending on the severity of presentation, some patients
will require surgical treatment, such as a craniotomy with
drainage.53 Ramey et al. suggest terminating anti-platelet
treatment in patients with established AvWS, but this is not
supported by data.71
Routine administration of platelets is debatable in ICH, be-
cause adverse outcomes have been noted, but it might be re-
quested in patients undergoing neurosurgical intervention.71
The significance of radiological screening of potential risk
factors for ICH is not established. A multidisciplinary ap-
proach to treatment and decision-making might be optimal
in this setting.
Treatment
The assessment of all stroke patients is performed using stan-
dardized examination tools, such as the National Institutes of
Health Stroke Scale, and a measure of consciousness, such as
the Glasgow Coma Scale, for the sake of monitoring the pa-
tient with reproducible, objective measurement tools. Intra-
venous recombinant tissue plasminogen activator is highly
effective for improving functional outcomes in general acute
ischaemic stroke patients, but there are no trials in
LVAD-related stroke patients. Thrombolysis may be ineffec-
tive because thrombi from within the CF-LVADs may have a
composition (fibrin and denatured protein) that is not been
amenable to thrombolysis.
Patients with CF-LVADs are likely to be at significantly
higher risk of symptomatic haemorrhagic transformation af-
ter systemic thrombolysis. Firstly, patients with CF-LVADs
are often taking warfarin and typically at least one
anti-platelet agent, and tend to have larger territorial infarcts,
which are all associated with a higher risk of haemorrhagic
conversion in several prediction scores. Secondly, the associ-
ation of systemic infection with ischaemic stroke increases
the likelihood a septic embolism, and thrombolysis in pa-
tients with bacterial endocarditis leads to high rate of
haemorrhagic complications (close to 20%).80 Thirdly, pa-
tients with CF-LVADs have an acquired vWF deficiency that
would increase the risk of haemorrhagic transformation.8
Because of the high risk for haemorrhagic transformation,
endovascular stroke therapy may provide specific clinical and
diagnostic benefits in patients with a CF-LVAD, avoiding
systemic fibrinolytic therapy in patients treated with
anticoagulation and anti-platelets. However, the risk of
haemorrhagic transformation with endovascular stroke ther-
apy appears like that of systemic thrombolysis.81
Treatment decisions for acute haemorrhagic stroke pa-
tients are based on whether the patient has had a primary
haemorrhagic stroke (intra-cerebral haemorrhage and sub-
arachnoid haemorrhage) or haemorrhagic transformation.
Other factors include the anti-thrombotic agents used, coag-
ulation profile, and platelet count. Regardless of aetiology,
the first focus of treatment is to establish the need for me-
chanical ventilation due to impaired alertness, in parallel with
preventing expansion of the haematoma. ICH is associated
with a very high in-hospital mortality of about 20%.67
Currently, the mainstay of therapy in haemorrhagic stroke
is reduction of BP and reversing coagulopathy, in line with
safety concerns regarding BP targets with specific devices.
The acute treatment of BP in the CF-LVAD patient with an
ICH is not well established in the guidelines for stroke, but
it would be reasonable to lower mean arterial pressure to
<90 mmHg, as suggested for primary stroke prevention in
CF-LVAD.82
The decision to reverse a coagulopathy is more complex.
The most recent ICH guidelines from the American Stroke As-
sociation suggest reversing warfarin with prothrombin com-
plex concentrates or FFP without a specific INR target.83
The decision about when to resume anticoagulation in the
ischaemic stroke patient without endocarditis is driven by the
presence, and likelihood, of developing haemorrhagic conver-
sion in the general ischaemic stroke patient. Generally, re-
sume warfarin at the same time as aspirin (without a
heparin bridge) within 24 h if haemorrhagic conversion is ab-
sent and the total infarct size is <50% of the middle cerebral
artery territory (given the association of large infarct size with
haemorrhagic conversion).67
If the patient is at high risk for haemorrhagic conversion,
such as with large infarcts with petechial bleeding, a head
computed tomography (CT) is repeated at 5 days and warfa-
rin is resumed at that point if there is no evidence of
haemorrhagic conversion.67
After a primary ICH in the general stroke patient, long-term
anticoagulation can be resumed for clear indications if there
is no lobar ICH due to cerebral amyloid angiopathy.
Early decompressive haemicraniectomy for large hemi-
spheric ischaemic strokes with somnolence and intact
brainstem reflexes (except loss of one pupillary response)
provides substantial mortality benefit (absolute risk reduction
78–29%) in patients <60 years of age.84 However, confound-
ing the care of patients with CF-LVADs, haemicraniectomy re-
quires withholding anticoagulation to prevent surgical site
bleeding until 4–8 weeks afterward when the cranioplasty is
placed. Post-operative management with anti-thrombotic
agents and long-term functional prognosis in large strokes in-
creases the complexity of the decision on whether to perform
haemicraniectomy.
There is a strong need to continue research into the risk
factors, natural history, complication rates, and acute stroke
treatment for patients with CF-LVADs.
The efficacy of treatment after stroke is also not well
known, with small series documenting results after reversing
anti coagulation in ICH, but not outcomes beyond death such
as functional statistics.85 This is notable because stroke can
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directly lead to death but more frequently leads to significant
disability. The latter can be particularly important to patients
with LVAD in whom complications from limited mobility can
be substantial, including loss of eligibility for transplantation
and infection.
Until there are more data, a multidisciplinary approach
tailored to the specific clinical need of patients is required in-
cluding input from neurologists/neurosurgeons/neuropsy-
chologists and those familiar with and routinely involved in
the care of these patients.67
• When a patient with LVAD presents with ischaemic stroke,
rule out background infection or even sepsis as a contrib-
uting factor.
• Because of anticoagulation issues of this group of patients,
beware of haemorrhagic conversion.
• Treatment of haemorrhagic stroke first includes lowering
MAP to below 90, and conversion of the anticoagulation
with FFP, or prothrombin complex concentrates.
Suspected pump thrombosis
Pump thrombosis is still a dreaded complication of both
short-term and long-term use of LVADs as it occurs in 2–
13% of the adult patients.86 Pump thrombosis is almost
non-existent with the use HM3 device unless ingestion of ma-
terial occurs within the device. In the first HM3-implanted pa-
tients, the clip used to secure the swivel point was not used
increasing the risk of a rare but catastrophic complication of
outflow graft twist with thrombus formation in the graft in
those patients.87
Pump thrombosis is the development of a clot within the
flow path of any component of the pump: the titanium inflow
cannula/the rotor or the outflow graft. The thrombus can be
created within the LVAD, or it can travel from either the left
atrium or the left ventricle or lodge in any of the pump
components.
Pump thrombosis is a life-threatening event, and thus,
prompt diagnosis and successful management are crucial, as
it can lead to one of the following: neurological event, periph-
eral thrombo-embolism, LVAD malfunction with reduced
flows and life-threatening haemodynamic impairment, car-
diogenic shock, and death.
When an LVAD patient arrives to the emergency depart-
ment (ED) with suspected pump thrombosis, first thrive for
patient stabilization; next, the source and location of the
thrombus must be identified, and the proper therapy must
be initiated.
Several therapeutic options are available according to the
location of the thrombus. While one can address both the in-
flow cannula and the outflow graft thrombus either medically
or surgically, for the outflow graft, the stenting approach is
also available.
In any scenario, the LVAD implanting centre must be
approached and transferring the patient to the LVAD centre
is preferred.
Diagnosis
Inflow cannula and intra-device thrombus
Left ventricular assist device thrombus that is located within
the pump has a very distinct appearance (Figure 1); once
seen, one can better understand the catastrophic conse-
quences of this event.88
Inflow cannula and intra-pump thrombus are suspected in
the setting of any of the following: signs of worsening HF
(progressive dyspnoea on exertion), acute changes in the
LVAD parameters (‘low-flow’ alarms and LVAD power spikes),
haemolysis (lactic dehydrogenase increase, haemoglobin
drop plasma-free haemoglobin rise, and darker urine), and
signs of distal embolization.
Once an LVAD thrombus is suspected, one should explore
the LVAD alarms and power spikes: if the decrease of power
and flow happens in a short period of time, an inflow pump
thrombosis is the more reasonable diagnosis. This suspicion
of intra-device or inflow cannula thrombus can be confirmed
using the following tools:
• Transthoracic echocardiogram—ramp studies:
Left ventricle enlargement
Opening of the aortic valve in each cycle
Worsening mitral regurgitation
Inflow cannula turbulence
Concern for a possible seen thrombus
Figure 1 Thrombus inside the HM II LVAD.
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• CT with angiography that will demonstrate no outflow
graft obstruction
Outflow graft obstruction/thrombosis
Although the outflow graft is the less prevalent site of a
pump thrombosis, the diagnostic process is very similar to
the one of an inflow cannula thrombosis with some
modification.
First, one should understand that while inflow cannula ob-
struction can occur only from the ‘inside’, outflow graft ob-
struction can occur also from an external pressure on the
graft.
The patient presentation will be very similar with
progressive dyspnoea on exertion, ‘low-flow’ alarms, and
LVAD power spikes. However, in this case, the decrease of
power and flow happens in a relatively ‘longer’ period of
time.
While the blood and urine haemolysis pattern may be like
the one seen in an inflow pump thrombosis, it might be
‘softer’; for example, the values will not be as high as seen
in an inflow pump thrombosis. Moreover, one should remem-
ber that outflow graft obstruction causing HF symptoms can
be also caused from external pressure on the graft; hence,
in some cases, no haemolysis will take place.
This suspicion of an outflow graft obstruction can be con-
firmed using the following tools89:
• Transthoracic echocardiogram—ramp studies:
Left ventricle enlargement
Opening of the aortic valve in every cycle
Worsening mitral regurgitation
Outflow graft turbulence
No thrombus is seen inside the left ventricle
• CT with angiography—outflow graft obstruction/stenosis
present
• Intravascular ultrasound—narrowing of the internal diam-
eter due to external pressure
Treatment
Once the diagnosis of pump thrombosis is confirmed, the fol-
lowing therapeutic protocols are advised, starting with med-
ical therapy that turns into surgical once failed:
• The INR levels adjusted to 2.5–3.5.
• If no change has occurred during the next 24 h, start
continuous heparin infusion to an activated partial throm-
boplastin time goal of 80–100 s. Activated partial throm-
boplastin times tend to overestimate anticoagulation,
and anti-XA monitoring might be used as well to assess ad-
equacy of therapy.
• If non-responsive or unstable, try thrombolysis with tissue
plasminogen activator started as 30 mg bolus followed by
infusion of the next 20 mg at the rate of 1 mg/min for the
next 20 min, followed with eptifibatide and intravenous
heparin 2 h after the tissue plasminogen activator
infusion.
• If yet non-responsive or unstable, pump exchange might
be needed. If the patient is unstable, skip the medical
treatment and go straight for a pump replacement or
put on venoarterial extracorporeal membrane oxygenation
for metabolic and end-organ rescue prior to pump
exchange.
If an outflow graft obstruction was diagnosed and a per-
cutaneous approach is applied, when balloon inflating does
not suffice, the use of Wallstent is preferred. The physiolog-
ical effect of reliving the outflow graft occlusion can be
seen immediately after deploying the stent by a reduction
of the power consumption and an increase in the pump
flow.
A word of caution regarding the use of thrombolysis must
be cleared. Its efficacy in treating LVAD thrombosis has been
questioned along the years and was debated because of in-
creased risk of bleeding; however, data were scarce. Lately,
Seese et al.84 have demonstrated that out of 26 patients that
received initial thrombolytic therapy, in only three patients a
successful treatment was achieved. Conversely, three pa-
tients suffered from major bleeding and two patients had a
new stroke. Furthermore, most patients undergoing throm-
bolytic therapy underwent subsequent device exchange.84
Hence, thrombolysis for an HMII pump thrombosis should
only be applied as a last resort due to the limited efficacy of
thrombolysis and the related increased risk of major bleeding
or stroke and surgical pump exchange is preferred. Regarding
the management of an HW pump thrombosis, as of 3 June
2021, the distribution of the HW has been discontinued;
therefore, in case of the need for pump exchange, the HW
would have to be replaced with the HM3. A surgical proce-
dure for such an LVAD exchange is not established yet, and
most centres do not have the needed experience in
performing such an exchange. Thus, the non-surgical ap-
proach to HW pump thrombosis must be exploited as far as
possible.
The use of thrombolytics in the case of pump
thrombosis is to be used with extreme caution considering
the increased risk of bleeding in the need for LVAD
exchange.
• Pump thrombosis is a life-threatening event that must be
addressed immediately.
• Once the patient is stabilized and diagnosed, promptly ini-
tiate medical treatment.
• Use increased anticoagulant therapy and stenting in out-
flow graft thrombus.
• If medical treatment fails, contact the implanting centre
for an advanced therapy.
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Chest pain
Chest pain in patients with LVADs is encountered commonly
not only immediately after surgery but also long after the de-
vice implantation. Chest pain was in some centres the second
most common ED presentation but lead to hospitalization in
only in 50% of cases. Chest pain can be caused by both car-
diac and non-cardiac causes.90 In another large
single-centre observational study, chest pain accounted for
4% of all the unplanned readmissions.91
In most cases, the pain is of non-cardiac origin with a broad
differential diagnosis. Chest pain in the LVAD-supported pa-
tient can be manifestation of post-pericardiotomy syndrome,
mechanical pain from the device–intrathoracic wall contacts
in slim patients or children, pneumonia/pleuritis, pneumo-
thorax, pneumomediastinum, oesophageal spasm or esopha-
gitis, cholecystitis or biliary colic, pancreatitis, peptic ulcer,
costochondritis, rib injury, or fracture. In some patients, chest
pain is vertebrogenic caused by the long-term unequal load
on the spine due to carrying the accessory bag on one shoul-
der only. Chest pain or discomfort can be caused by the pump
body itself, most often when lying on the left side. Rule out
pocket infection if pain in this area is combined with fever
or increased inflammatory activity.
• Although less frequent, chest pain in LVAD-supported pa-
tients can be also from cardiac origin like myocardial in-
farction, pericarditis, aortic dissection, pulmonary
embolism, or implantable cardioverter defibrillator dis-
charge. The seventh INTERMACS report indicates myocar-
dial infarction rate of 0.06 (events per 100 patient-
months) during first 12 months after implantation.92 Myo-
cardial infarction may be caused not only by a rupture of
atherosclerotic plaque but also by a thrombo-embolic
complication. Embolus may originate from the left ventri-
cle or atria but may be due to pump thrombosis or throm-
bosis in the aortic root. An evolving thrombus in the aortic
root or in the aortic valve itself can cause acute obstruc-
tion of the coronary arteries. An echocardiography or even
CT angiography should be used to rule out this potentially
catastrophic event. Optimal treatment of myocardial in-
farction in LVAD patients is not clear. Primary coronary in-
tervention approach favouring rapid symptomatic relief,
reducing risk of malignant arrhythmia, and protection of
right ventricular function have been reported.88 Although
the levels of the two biomarkers: N-terminal pro-brain na-
triuretic peptide and troponin are expected to decline or
increase respectively because of left ventricular unloading
or the occurrence of myocardial infarction, the clinical sig-
nificance of these two biomarkers in LVAD-supported pa-
tients has not been thoroughly explored yet.
• Chest pain in most cases is of non-cardiac origin and diffi-
cult to diagnose.
• Chest pain in LVAD-supported patients’ needs to be thor-
oughly assessed.
• Chest pain from cardiac origin in LVAD patients is not com-
mon but can be life-threatening despite the LVAD support.
• Have acute myocardial infarction treatment as in
non-LVAD patients with primary coronary intervention af-
ter consulting an LVAD specialist.
Syncope in left ventricular assist
device-supported patients
Syncope is defined as a total loss of consciousness, due to ce-
rebral hypoperfusion, characterized by a rapid onset, short
duration, and spontaneous complete recovery.93 Occurrence
of syncope has been described in LVAD patients.75
In daily clinical practice, syncope and orthostatic symp-
toms like dizziness, blurry vision, confusion, and nausea can
be challenging in LVAD patients.
Prevalence of dizziness and syncope has been described to
occur in 13% of LVAD patients. Up to 30% patients suffer
from orthostatic hypotension.
Aetiology for syncope in these patients includes ortho-
static hypotension, cardiac factors like arrhythmias, and
vasodepressive neurogenic and device-specific mechanical
factors.
Left ventricular assist device patients show an increased
susceptibility for orthostatic hypotension, resulting from
pathophysiological properties in CF and in HF in general. This
includes an abnormal sympathetic tone with a marked de-
crease in vasoconstrictive function, an offloading of carotid
and aortic baroreceptors causing a loss of compensatory
mechanisms with positional changes.94
Further contributors to orthostatic hypotension include
low intravascular volume state, medications with vasodilator
properties, poor right ventricular function, and co-
morbidities like diabetes mellitus leading to secondary
autonomic failure. Device-specific factors like malposition
of the inflow cannula receive special attention. Pathophysi-
ology of syncope in LVAD patients can be complex resulting
from different predisposing factors at the same time.
Positional changes from supine to upright in even mildly
hypovolemic and diabetic LVAD-supported patient can cause
dizziness and syncope.
It is crucial to understand the mechanisms behind these
events by adequately performing diagnostic procedures to
tailor individualized therapeutic regimens.
Diagnosis includes careful history taking, thorough physical
examination, supine and standing BP measurements, imme-
diate electrocardiogram (ECG) monitoring when there is
suspicion of arrhythmia, and blood tests (haemoglobin,
kidney function tests, uric acid, etc.). Advanced evaluation
with echocardiography is essential to assess septum position,
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inflow cannula position, right ventricular function, and
volume status. A head-up tilt test can be performed when
there is suspicion of syncope due to orthostatic hypotension.
Interrogation of LVAD parameters like power, flow, revolu-
tions per minute, pulsatility index, and the occurrence of
suction events completes diagnosis. LVAD alarms must be
scrutinized. In special situations, interdisciplinary discussion
with the implanting cardiac surgeon and technicians can be
very helpful.
Therapy is individually tailored according to the underly-
ing reasons for syncope. In case of orthostasis, correct low-
volume status (higher fluid intake and correction of anae-
mia) and remove vasodilatory drugs (especially α1-receptors)
or drugs associated with dysautonomia (amiodarone).
Exercise and the use of compression stockings can be help-
ful. Administration of fludrocortisone as well as the use of
the vasopressor midodrine has been described (3). In case
of excessive unloading or low-flow alarms of the left
ventricle despite correction of volume status, adapt pump
speed.
• The LVAD patients are prone to syncope due to orthostatic
hypotension.
• Always evaluate the patients for dehydration, anaemia and
arrhythmia with ECG, echocardiography, blood tests, and
pacemaker interrogation.
• When suction event is suspected, perform fluid resuscita-
tion and consult the LVAD specialist.
Death declaration in the emergency
department
The number of LVADs implanted is expanding all around the
globe. Thus, complications that were once seen sporadically
are now seen in increasing numbers. Furthermore, LVADs
are constantly becoming better and more reliable, and the
frequency of LVAD-related side effects is declining. Thus,
the life expectancy of the LVAD-supported patients is ex-
tended, exposing the patients to new complications and the
physicians to new dilemmas. The following chapter will re-
view the process of a patient arriving to the ED addressing
the option that the cardiopulmonary resuscitation (CPR) pro-
cess was not successful.
Left ventricular assist device patients can be brought to
the ED by their family members/first responders while being
resuscitated. Management of the unresponsive LVAD-sup-
ported patient hospitalized in the non-intensive care setting
has been described91 but not the management of such a pa-
tient brought to the ED been on CPR.
A suggestion for the management of the non-responsive
LVAD-supported patient brought to the ED is presented.
1 Continue CPR.
2 Ventilate if not yet performed by the emergency medical
service.
3 Assess LVAD function. If not functioning, reconnect the
LVAD to electrical supply if possible.
4 Perform an ECG.
5 Perform basic echocardiography to assess heart function.
6 If not asystole and there is some cardiac function,
assess organ perfusion by performing carotid and femoral
Doppler.
7 If LVAD is functioning and the perfusion is found to be ap-
propriate, call for a stroke code.
8 If no perfusion, consider advance therapies as venoarterial
extracorporeal membrane oxygenation depending on the
patient’s status, the duration of the CPR, and other co-
morbidities.
9 Consider death declaration according to the local law and
contact the ventricular assist device unit for disconnecting
the device.
The World Health Organization has set Clinical Criteria
for the Determination of Death,95 but because the declara-
tion of death relies on the law of each country, the pre-
sented protocol is only a general point of view,
emphasizing the obligation to declare death according to
the local law.
The World Health Organization clinical criteria for the de-
termination of death are as follows:
1 Neurological arrest:
a No other reason was identified:
i Good ventilation, oxygenation, and perfusion
ii Not hypothermic
iii No metabolic or endocrinological issues
iv No acid–base or electrolytes issues
v No toxic substances were used
vi No neuromuscular blockers or neurodepressant drugs
were given
b Coma, no brain stem reflexes, and apnoea
c Confirmed by electroencephalogram, brain perfusion,
and observation
d Declaration of death
2 Cardiocirculatory arrest:
a No response, gasping, and no circulation
b CPR failed: no pulse, no heart sounds, no breathing, and
no pupil light response
c Echocardiogram, arterial line, or ECG confirmed all the
above
d Wait for 5 min to verify no spontaneous recovery and
then declare death
Using the World Health Organization (WHO) criteria,
comparing between the different parameters needed to
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declare death in the LVAD patient and in the non-LVAD
patient, there are no differences in most parameters
such as
• neurological function,
• check pupils for position and response to light,
• check response to tactile stimuli, and
• check for spontaneous respiration.
Some of the WHO criteria needed modification for the
LVAD-supported patients. The difference lies within the 2b
criteria: ‘CPR failed: no pulse, no heart sounds, no breathing,
and no pupil light response’. Checking for pulse and heart
sounds is challenging in LVAD patient, and therefore, declara-
tion of death must be verified using advance tools like ECG,
echocardiography, and PETCO2 under 10.
There are no major issues related to the burial of a de-
ceased LVAD-supported patient. Although not dealt in the
medical literature, no adverse events are expected if the de-
ceased is sent to the crematorium.
• To declare death in an LVAD patient, one must verify
whether the LVAD is functioning or not and troubleshoot
the device.
• Use advanced tools and the WHO criteria to declare if
there is circulatory or neurological arrest.
• Follow the local law to declare death!
Conclusion
Despite the more frequent use of new-generation LVADs, the
growing number of LVAD-supported patients and their im-
proved survival is expected to increase their need for ED sup-
port due to LVAD-related and non-LVAD-related medical
emergencies. The understanding, prompt, and structured ap-
proach to the LVAD-supported patient presenting at the ED
with bleeding, neurological event, pump thrombosis, chest
pain, or syncope is critical for the successful management
and longer survival of these patients. When everything fails,
the challenging declaration of death in the LVAD-supported
patient needs to be made according to the local regulations.
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